[ANALYSIS OF PREVALENCE OF CHRONIC VIRAL HEPATITIS IN KAZAKHSTAN IN 2012-2016]

The introduction of vaccinations against hepatitis B into the preventive vaccination calendar has led to a significant decrease in the incidence of viral hepatitis B among the population under 18 years of age. The goal is to analyze the effect of viral hepatitis in the Republic of Kazakhstan. Our studies of a 5-year cross-section showed that the incidence of chronic viral hepatitis B tends to decline. So, if the number of CHB diseases in 2012 was at the level of 35.4 cases per 100 thousand population, then in 2016 this figure decreased by 5.8 cases (↓ 16.4%) and amounted to 29.6 diseases per 100 thousand. During the period under review, a significant decrease in CHB cases was recorded in 2015 (27.9 per 100 thousand people), which was further accompanied by a slight increase in the incidence in 2016 by 6% or 1.7 cases per 100 thousand people. However, there is an increase in the incidence of delta hepatitis, for example, for the period from 2012 to 2016, the incidence of CVH from delta of citizens over 18 years old increased by 50% and amounted to 0.57 cases per 100 thousand people. According to recent epidemiological studies, the prevalence of hepatitis C virus infection (estimated from anti-HCV detection) may vary by region, but the prevalence is 3.1% nationwide. In terms of the population of the country in 2013, the number of patients with a positive test for anti-HCV was 483 thousand people. Among them, viremia occurs in almost 75% of people. If we recalculate this number of patients per population of the country, we will see that the prevalence of viremia, i.e. the prevalence of chronic hepatitis C infection in Kazakhstan is 2.4%, which corresponds to 362 thousand patients in 2013. Taking into account the increase in access to highly active antiviral agents in the Republic of Kazakhstan, the paradigm of predicted elimination of hepatitis C is presented. The issue of studying liver steatosis becomes relevant, in connection with the increasing global growth of metabolic disorders, including in the Republic of Kazakhstan.